Cargando…

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

BACKGROUND: ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study (NCT01284192) assessed the safety, pharmacokinetic profile, and antitum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tianhong, LoRusso, Patricia, Maitland, Michael L., Ou, Sai-Hong Ignatius, Bahceci, Erkut, Ball, Howard A., Park, Jung Wook, Yuen, Geoffrey, Tolcher, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786998/ https://www.ncbi.nlm.nih.gov/pubmed/26966027 http://dx.doi.org/10.1186/s13045-016-0254-5

Ejemplares similares

Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study
por: Ono, Akira, et al.
Publicado: (2020)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014)

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
por: Smith, David C., et al.
Publicado: (2018)

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022)

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
por: Shi, Yuankai, et al.
Publicado: (2022)

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2021)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Triglyceride-glucose index linked to all-cause mortality in critically ill patients: a cohort of 3026 patients
por: Liao, Ying, et al.
Publicado: (2022)

A comparative study of diagnostic accuracy in 3026 pleural biopsies and matched pleural effusion cytology with clinical correlation
por: Poon, Ivan K., et al.
Publicado: (2022)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
por: Bendell, Johanna C, et al.
Publicado: (2017)

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies
por: Rixe, Olivier, et al.
Publicado: (2015)

A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
por: Carducci, Michael A., et al.
Publicado: (2023)

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu, Viola W, et al.
Publicado: (2018)

Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies
por: Desai, Amit, et al.
Publicado: (2020)

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
por: Shimizu, Toshio, et al.
Publicado: (2023)

Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)
por: Atreya, Chintamani, et al.
Publicado: (2019)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

Radiation Dose Escalation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance Local and Distant Antitumor Effect in Murine Osteosarcoma
por: Takenaka, Wataru, et al.
Publicado: (2020)

Neural network dose prediction for rectal spacer stratification in dose‐escalated prostate radiotherapy
por: Thomas, Christopher, et al.
Publicado: (2022)

Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer
por: Jo, Sunmi, et al.
Publicado: (2016)

Dose‐escalation strategies which use subgroup information
por: Cotterill, Amy, et al.
Publicado: (2018)

Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma
por: Tensaouti, Fatima, et al.
Publicado: (2019)

Safety and tolerability of escalating cannabinoid doses in healthy cats
por: Kulpa, Justyna E, et al.
Publicado: (2021)

Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
por: Rozental, Aaron J., et al.
Publicado: (2022)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ubn3l69a7gr04p0k3k0d5jr9g9